FOR RESEARCH USE ONLY
Early human researchMetabolic research

AOD9604

Modified C-terminal fragment of human growth hormone researched for lipolysis and fat metabolism.

01Adipose metabolism02hGH fragment research03Cartilage models
Molecular signature / aod9604
Structural identity

Modified C-terminal human growth-hormone fragment

Also known as

Advanced Obesity Drug 9604 · hGH fragment 176-191 analogue

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

AOD9604 is a modified fragment of the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added disulphide bridge to enhance stability. Originally developed as an anti-obesity agent at Monash University, it isolates the fat-mobilising activity of hGH without the growth-promoting, insulin-resistance or IGF-1-elevating effects of the full hormone. It has progressed through Phase 2 clinical trials for obesity and is also studied for cartilage repair and metabolic applications.

The research question

AOD9604 was designed to investigate fat metabolism without engaging the full growth-hormone receptor programme. The important distinction is not simply whether lipolysis changes in a model, but whether a durable and clinically meaningful outcome follows.

Section 02

Mechanism & research themes

Stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (formation of new adipose tissue) via mechanisms distinct from the GH receptor — believed to involve β3-adrenergic receptor pathways in adipose tissue. Does not bind the GH receptor, so it does not elevate IGF-1, impair glucose tolerance or stimulate skeletal growth.

01

Targeted lipolysis in adipose tissue without GH-receptor activation

02

No elevation of IGF-1, blood glucose or insulin resistance in trials

03

Phase 2 data showing favourable body-composition shifts

04

Investigational support for cartilage repair and osteoarthritis research

05

Favourable safety profile across human trials to date

06

Compatible with GLP-1 / metabolic peptide protocols in research stacks

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Human obesity studies have not produced the magnitude or consistency of effect seen with later incretin-based treatments. Mechanistic rationale is stronger than the established efficacy case.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 250–500mcg subcutaneously once daily, typically administered in a fasted morning state to align with peak lipolytic activity. Cycles often run 8–12 weeks. Higher 500mcg–1mg daily doses are reported in obesity-focused research.

Reported persistence

Plasma half-life approximately 30 minutes; biological activity on adipocytes persists longer through downstream signalling.

Calculator starting point

0.3 mg per reference dose

6 doses per week · 12-week cycle

2 mL default reconstitution volume

300 mcg/day SC, typically morning fasted.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate AOD9604
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently down the side of the vial — do not shake.

Storage reference

Lyophilised: 2–8°C, stable approximately 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Magnitude of weight loss in human trials has been modest compared with GLP-1-class agents.

L2

Most efficacy data sits at Phase 2; no Phase 3 obesity approval has been completed.

L3

Mild injection-site reactions reported; long-term safety data beyond trial durations remains limited.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only